Romain Guiho

List of Publications by Citations

18 papers	497 citations	10 h-index	18 g-index
18 ext. papers	700 ext. citations	5.4 avg, IF	4.26 L-index

#	Paper	IF	Citations
18	Cardiac glycosides are broad-spectrum senolytics. *Nature Metabolism*, **2019**, 1, 1074-1088	14.6	114
17	HGG-07. RADIATION INDUCED SENESCENCE IN DIFFUSE INTRINSIC PONTINE GLIOMA CELLS REVEALS SELECTIVE VULNERABILITY TO BCL-XL INHIBITION. *Neuro-Oncology*, **2021**, 23, i18-i18	1	78
16	LGG-11. BH3-MIMETICS TARGETING BCL-XL SELECTIVELY IMPACT THE SENESCENT COMPARTMENT OF PILOCYTIC ASTROCYTOMA. *Neuro-Oncology*, **2021**, 23, i33-i34	1	78
15	Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target. *Acta Neuropathologica*, **2018**, 135, 757-777	14.3	64
14	Galactose-modified duocarmycin prodrugs as senolytics. *Aging Cell*, **2020**, 19, e13133	9.9	37
13	The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma. *Clinical Cancer Research*, **2019**, 25, 1851-1866	12.9	26
12	TRAIL delivered by mesenchymal stromal/stem cells counteracts tumor development in orthotopic Ewing sarcoma models. *International Journal of Cancer*, **2016**, 139, 2802-2811	7.5	23
11	Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma. *Oncotarget*, **2014**, 5, 7805-19	3.3	20
10	TRAIL-based therapy in pediatric bone tumors: how to overcome resistance. *Future Oncology*, **2015**, 11, 535-42	3.6	14
9	SHH pathway inhibition is protumourigenic in adamantinomatous craniopharyngioma. *Endocrine-Related Cancer*, **2019**, 26, 355-366	5.7	13
8	A functional, new short isoform of death receptor 4 in Ewing sarcoma cell lines may be involved in TRAIL sensitivity/resistance mechanisms. *Molecular Cancer Research*, **2012**, 10, 336-46	6.6	9
7	Cell senescence in neuropathology: A focus on neurodegeneration and tumours. *Neuropathology and Applied Neurobiology*, **2021**, 47, 359-378	5.2	9
6	In vitro and in vivo discrepancy in inducing apoptosis by mesenchymal stromal cells delivering membrane-bound tumor necrosis factor-related apoptosis inducing ligand in osteosarcoma pre-clinical models. *Cytotherapy*, **2018**, 20, 1037-1045	4.8	7
5	Jaw osteosarcoma models in mice: first description. *Journal of Translational Medicine*, **2019**, 17, 56	8.5	4
4	Preclinical evidence of positive effect of l-MTP-PE alone or combined with zoledronic acid in osteosarcoma.. *Journal of Clinical Oncology*, **2014**, 32, 10048-10048	2.2	1
3	LGG-09. SENOLYTIC AGENT NAVITOCLAX TARGETS VINBLASTINE- AND MAPK INHIBITORS-INDUCED SENESCENT TUMOUR CELLS IN PAEDIATRIC LOW GRADE GLIOMAS. *Neuro-Oncology*, **2021**, 23, i33-i33	1	0
2	LGG-17. Preventing recurrence: targeting molecular mechanisms driving tumor growth rebound after MAPKi withdrawal in pediatric low-grade glioma. *Neuro-Oncology*, **2022**, 24, i91-i91	1	

1 LGG-18. Inhibition of Bcl-xL targets the senescent compartment of pilocytic astrocytoma. *Neuro-Oncology*, **2022**, 24, i91-i92 1